Although further quantitative analysis is needed, it seems that when high levels of MerTK are present before treatment starts, the tumor cells may take advantage of other mechanisms to survive BRAF or combined BRAF/MEK blockade. This evidence concerns the gene MAP2K7 and neoplasm.